Engineered immune cells take on tough blood cancers in early trial
NCT ID NCT02935257
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The main goals are to see if the treatment is safe and can be manufactured successfully.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR T-cells (genetically modified immune cells targeting CD19)
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat blood cancers that have not responded to standard therapies.
- What could go wrong
- This is an early Phase I trial with a small number of participants, so results may not apply broadly. There are risks of severe side effects like cytokine release syndrome and neurological toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College London Hospital
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope